Trade Alzamend Neuro, Inc. - ALZN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.0318 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
| Prev. Close* | 1.0591 |
| Open* | 1.0191 |
| 1-Year Change* | -7.11% |
| Day's Range* | 1.0091 - 1.0291 |
| 52 wk Range | 1.06-19.20 |
| Average Volume (10 days) | 532.05K |
| Average Volume (3 months) | 2.13M |
| Market Cap | 7.05M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 6.47M |
| Revenue | N/A |
| EPS | -2.36 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Dec 12, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 8, 2023 | 1.0591 | -0.0500 | -4.51% | 1.1091 | 1.1091 | 1.0291 |
| Dec 7, 2023 | 1.0891 | 0.0300 | 2.83% | 1.0591 | 1.1091 | 1.0391 |
| Dec 6, 2023 | 1.0591 | 0.0500 | 4.95% | 1.0091 | 1.0691 | 1.0091 |
| Dec 5, 2023 | 1.0191 | -0.0200 | -1.92% | 1.0391 | 1.0391 | 1.0091 |
| Dec 4, 2023 | 1.0291 | -0.0800 | -7.21% | 1.1091 | 1.1091 | 1.0091 |
| Dec 1, 2023 | 1.1091 | -0.0400 | -3.48% | 1.1491 | 1.1691 | 1.0991 |
| Nov 30, 2023 | 1.1991 | 0.1000 | 9.10% | 1.0991 | 1.1991 | 1.0891 |
| Nov 29, 2023 | 1.1591 | 0.1600 | 16.01% | 0.9991 | 1.1991 | 0.9991 |
| Nov 28, 2023 | 1.0391 | 0.0700 | 7.22% | 0.9691 | 1.0391 | 0.9691 |
| Nov 27, 2023 | 0.9991 | 0.0100 | 1.01% | 0.9891 | 1.0091 | 0.9591 |
| Nov 24, 2023 | 1.0191 | -0.0200 | -1.92% | 1.0391 | 1.0591 | 0.9991 |
| Nov 22, 2023 | 1.0491 | -0.0100 | -0.94% | 1.0591 | 1.0691 | 0.9764 |
| Nov 21, 2023 | 1.0791 | -0.1100 | -9.25% | 1.1891 | 1.1991 | 1.0491 |
| Nov 20, 2023 | 1.3591 | -0.3600 | -20.94% | 1.7191 | 1.8991 | 1.1291 |
| Nov 17, 2023 | 1.6491 | 0.2300 | 16.21% | 1.4191 | 1.6991 | 1.3991 |
| Nov 16, 2023 | 1.4791 | -0.0200 | -1.33% | 1.4991 | 1.4991 | 1.4091 |
| Nov 15, 2023 | 1.4991 | 0.1300 | 9.50% | 1.3691 | 1.5491 | 1.3691 |
| Nov 14, 2023 | 1.3891 | 0.0800 | 6.11% | 1.3091 | 1.4291 | 1.3091 |
| Nov 13, 2023 | 1.3591 | -0.0800 | -5.56% | 1.4391 | 1.4391 | 1.3191 |
| Nov 10, 2023 | 1.4491 | 0.0500 | 3.57% | 1.3991 | 1.4491 | 1.3991 |
Alzamend Neuro, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Tuesday, December 12, 2023 | ||
| Time (UTC) 21:00 | Country US
| Event Q2 2024 Alzamend Neuro Inc Earnings Release Q2 2024 Alzamend Neuro Inc Earnings ReleaseForecast -Previous - |
| Friday, March 15, 2024 | ||
| Time (UTC) 20:00 | Country US
| Event Q3 2024 Alzamend Neuro Inc Earnings Release Q3 2024 Alzamend Neuro Inc Earnings ReleaseForecast -Previous - |
| Thursday, April 25, 2024 | ||
| Time (UTC) 16:00 | Country US
| Event Alzamend Neuro Inc Annual Shareholders Meeting Alzamend Neuro Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 14.8705 | 12.3155 | 4.88947 | 4.42416 | 5.00888 |
| Selling/General/Admin. Expenses, Total | 7.42461 | 7.11822 | 3.64117 | 3.35474 | 1.3088 |
| Research & Development | 7.44586 | 5.20131 | 1.31072 | 1.06942 | 3.70008 |
| Operating Income | -14.8705 | -12.3155 | -4.88947 | -4.42416 | -5.00888 |
| Interest Income (Expense), Net Non-Operating | -0.0077 | -0.04652 | -0.15709 | 0.01393 | 0.14639 |
| Net Income Before Taxes | -14.8782 | -12.3621 | -5.04657 | -4.41024 | -4.8625 |
| Net Income After Taxes | -14.8782 | -12.3621 | -5.04657 | -4.41024 | -4.8625 |
| Net Income Before Extra. Items | -14.8782 | -12.3621 | -5.04657 | -4.41024 | -4.8625 |
| Net Income | -14.8782 | -12.3621 | -5.04657 | -4.41024 | -4.8625 |
| Income Available to Common Excl. Extra. Items | -14.8782 | -12.3621 | -5.04657 | -4.41024 | -4.8625 |
| Income Available to Common Incl. Extra. Items | -14.8782 | -12.3621 | -5.04657 | -4.41024 | -4.8625 |
| Diluted Net Income | -14.8782 | -12.3621 | -5.04657 | -4.41024 | -4.8625 |
| Diluted Weighted Average Shares | 97.519 | 89.0953 | 84.9295 | 84.9295 | 84.9295 |
| Diluted EPS Excluding Extraordinary Items | -0.15257 | -0.13875 | -0.05942 | -0.05193 | -0.05725 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Diluted Normalized EPS | -0.15257 | -0.1388 | -0.06016 | -0.05193 | -0.05725 |
| Unusual Expense (Income) | 0 | -0.004 | -0.06242 |
| Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 3.52593 | 3.30501 | 5.42351 | 3.1064 | 3.03554 |
| Selling/General/Admin. Expenses, Total | 1.15979 | 1.65694 | 2.53467 | 1.57342 | 1.65959 |
| Research & Development | 2.36614 | 1.64807 | 2.88885 | 1.53299 | 1.37595 |
| Unusual Expense (Income) | 0 | ||||
| Operating Income | -3.52593 | -3.30501 | -5.42351 | -3.1064 | -3.03554 |
| Interest Income (Expense), Net Non-Operating | -0.00184 | -0.00052 | -0.00206 | -0.00359 | -0.00153 |
| Net Income Before Taxes | -3.52777 | -3.30553 | -5.42557 | -3.10999 | -3.03707 |
| Net Income After Taxes | -3.52777 | -3.30553 | -5.42557 | -3.10999 | -3.03707 |
| Net Income Before Extra. Items | -3.52777 | -3.30553 | -5.42557 | -3.10999 | -3.03707 |
| Net Income | -3.52777 | -3.30553 | -5.42557 | -3.10999 | -3.03707 |
| Income Available to Common Excl. Extra. Items | -3.52777 | -3.30553 | -5.42557 | -3.10999 | -3.03707 |
| Income Available to Common Incl. Extra. Items | -3.52777 | -3.30553 | -5.42557 | -3.10999 | -3.03707 |
| Diluted Net Income | -3.52777 | -3.30553 | -5.42557 | -3.10999 | -3.03707 |
| Diluted Weighted Average Shares | 98.4401 | 96.7796 | 98.3262 | 97.4884 | 97.4818 |
| Diluted EPS Excluding Extraordinary Items | -0.03584 | -0.03416 | -0.05518 | -0.0319 | -0.03116 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.03584 | -0.03416 | -0.05518 | -0.0319 | -0.03116 |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total Current Assets | 5.83578 | 14.4135 | 2.91259 | 1.81402 | 1.50092 |
| Cash and Short Term Investments | 5.14086 | 14.0638 | 1.92927 | 0.09029 | 0.04261 |
| Cash | 5.14086 | 14.0638 | 1.92927 | 0.09029 | 0.04261 |
| Total Receivables, Net | 0 | 0.01621 | 0.19428 | 0.28535 | |
| Accounts Receivable - Trade, Net | 0 | 0.10092 | 0.20592 | ||
| Prepaid Expenses | 0.69492 | 0.34972 | 0.61461 | 1.52945 | 1.17296 |
| Total Assets | 5.91563 | 14.5164 | 2.91259 | 1.81402 | 1.50092 |
| Total Current Liabilities | 2.87012 | 1.16493 | 0.89964 | 0.99231 | 1.184 |
| Payable/Accrued | 2.87012 | 1.16285 | 0.50359 | 0.92964 | 1.10467 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.3353 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0.00208 | 0.06075 | 0.06267 | 0.07933 |
| Total Liabilities | 2.87012 | 1.16493 | 0.89964 | 0.99231 | 1.184 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 3.0455 | 13.3515 | 2.01295 | 0.82171 | 0.31692 |
| Redeemable Preferred Stock | 0 | 0 | 0.00008 | 0.00008 | 0.00008 |
| Common Stock | 0.00969 | 0.00955 | 0.00674 | 0.00648 | 0.00619 |
| Additional Paid-In Capital | 61.9918 | 57.4198 | 33.7219 | 27.5842 | 22.6863 |
| Retained Earnings (Accumulated Deficit) | -44.0727 | -29.1945 | -16.8324 | -11.7859 | -7.37563 |
| Other Equity, Total | -14.8833 | -14.8833 | -14.8833 | -14.9832 | -15 |
| Total Liabilities & Shareholders’ Equity | 5.91563 | 14.5164 | 2.91259 | 1.81402 | 1.50092 |
| Total Common Shares Outstanding | 6.463 | 6.36577 | 5.66225 | 5.66225 | 5.66225 |
| Other Current Assets, Total | 0.3525 | ||||
| Property/Plant/Equipment, Total - Net | 0.07984 | 0.10291 |
| Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 2.4136 | 5.83578 | 8.41681 | 10.3344 | 12.1147 |
| Cash and Short Term Investments | 1.69542 | 5.14086 | 7.37584 | 9.18281 | 11.5271 |
| Cash | 1.69542 | 5.14086 | 7.37584 | 9.18281 | 11.5271 |
| Total Receivables, Net | 0.00941 | ||||
| Accounts Receivable - Trade, Net | |||||
| Prepaid Expenses | 0.71819 | 0.69492 | 1.04097 | 1.15158 | 0.57813 |
| Total Assets | 2.62801 | 5.91563 | 8.50198 | 10.4249 | 12.2105 |
| Total Current Liabilities | 2.74089 | 2.87012 | 2.64247 | 1.63745 | 1.0287 |
| Payable/Accrued | 2.74089 | 2.87012 | 2.64247 | 0.64812 | 1.0287 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 0 | 0.98933 | 0 | |
| Total Liabilities | 2.74089 | 2.87012 | 2.64247 | 1.63745 | 1.0287 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | -0.11288 | 3.0455 | 5.85951 | 8.78742 | 11.1818 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00969 | 0.00969 | 0.00964 | 0.00955 | 0.00955 |
| Additional Paid-In Capital | 62.3611 | 61.9918 | 61.5003 | 59.0027 | 58.2871 |
| Retained Earnings (Accumulated Deficit) | -47.6004 | -44.0727 | -40.7671 | -35.3416 | -32.2316 |
| Other Equity, Total | -14.8833 | -14.8833 | -14.8833 | -14.8833 | -14.8833 |
| Total Liabilities & Shareholders’ Equity | 2.62801 | 5.91563 | 8.50198 | 10.4249 | 12.2105 |
| Total Common Shares Outstanding | 6.463 | 6.463 | 6.42883 | 6.3666 | 6.36577 |
| Other Current Assets, Total | |||||
| Property/Plant/Equipment, Total - Net | 0.2144 | 0.07984 | 0.08517 | 0.09049 | 0.09581 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Net income/Starting Line | -12.3621 | -5.04657 | -4.41024 | -4.8625 |
| Cash From Operating Activities | -6.61399 | -2.71203 | -2.34579 | -1.0452 |
| Non-Cash Items | 4.41734 | 2.48699 | 2.36379 | 2.58743 |
| Changes in Working Capital | 1.32718 | -0.15245 | -0.29935 | 1.22987 |
| Cash From Investing Activities | -0.10646 | 0.10092 | 0.105 | 0.23409 |
| Other Investing Cash Flow Items, Total | 0 | 0.10092 | 0.105 | 0.23409 |
| Cash From Financing Activities | 18.855 | 4.4501 | 2.28847 | 0.30872 |
| Financing Cash Flow Items | -0.05867 | 1.94799 | 0.00013 | 0.0727 |
| Issuance (Retirement) of Stock, Net | 18.9137 | 2.1 | 2.28834 | 0.23602 |
| Net Change in Cash | 12.1345 | 1.83899 | 0.04768 | -0.5024 |
| Issuance (Retirement) of Debt, Net | 0 | 0.40211 | ||
| Cash From Operating Activities | 0.00355 | |||
| Capital Expenditures | -0.10646 |
| Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -11.5726 | -6.14707 | -3.03707 | -12.3621 | -8.49266 |
| Cash From Operating Activities | -6.68797 | -4.881 | -2.53669 | -6.61399 | -5.05164 |
| Non-Cash Items | 3.0913 | 1.58298 | 0.86734 | 4.41734 | 3.16357 |
| Changes in Working Capital | 1.77563 | -0.32933 | -0.37405 | 1.32718 | 0.27745 |
| Cash From Investing Activities | -0.10646 | 0 | |||
| Other Investing Cash Flow Items, Total | 0 | 0 | |||
| Cash From Financing Activities | 0 | 0 | 0 | 18.855 | 14.9127 |
| Financing Cash Flow Items | -0.05867 | 0 | |||
| Issuance (Retirement) of Stock, Net | 0 | 0 | 0 | 18.9137 | 14.9127 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | |||
| Net Change in Cash | -6.68797 | -4.881 | -2.53669 | 12.1345 | 9.86102 |
| Cash From Operating Activities | 0.01774 | 0.01242 | 0.0071 | 0.00355 | |
| Capital Expenditures | -0.10646 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Alzamend Neuro, Inc. Company profile
About Alzamend Neuro Inc
Alzamend Neuro, Inc. is a preclinical stage biopharmaceutical company focused on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The Company's pipeline consists of two therapeutic drug candidates: AL001 and AL002. The AL001 is a cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001 or LiProSal, through two royalty-bearing worldwide licenses from the University of South Florida Research Foundation, Inc. (licensor). AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as AL002 or CA022W, through a royalty-bearing worldwide license from the licensor.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Alzamend Neuro Inc revenues was not reported. Net loss increased from $3.8M to $8.5M. Higher net loss reflects Research and development - Bal increase from $953K to $3.2M (expense), Stock-based Compensation in SGA increase of 67% to $2.8M (expense), General and administrative - Bal increase from $547K to $1.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
3480 Peachtree Road NE,
Second Floor, Suite 103
ATLANTA
GEORGIA 30326
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com